contentSlug

type

ContentPage_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentPage_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  createdAt
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
    forum {
      threadUrl
    }
    defaultInstrument {
      symbol
      id
    }
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  createdAt
  changedAt
  isPremium
  authors {
    __typename
    name
    pageUrl
    id
  }
  companies {
    name
    pageUrl
    id
  }
  tags {
    name
    id
  }
  ... on Video {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
  ... on Webcast {
    liveTime
    videoUrl
    videoEmbedUrl(location: "inderes")
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        threadUrl
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        symbol
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
      researchContentUrl
      researchContent {
        title
        lang
        pdfUrl
        relatedContent {
          __typename
          ...PublishingDetails
          ...Reactions
          id
        }
        content {
          title
          lang
          htmlBody
          publishedAt
          createdAt
          changedAt
          isOutdated
          isPremium
        }
      }
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
            nav
            navPerShare
            opexOfNav
            quarterlySharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


nexstim-conference-feedback-brainlab-is-set-to-scale-nbs-systems-nuways-ag-research

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

changedAt

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Kiitos Antti. Ammattilaisella on vastaukset aina valmiina

Oisko täällä osaavia, että saadaan myynti lentoon                    nexstim.com              Nexstim - Careers / Jobs

Muistaakseni parhaimmillaan on ollu +500k laitekauppoja. Hilmassa tietysti näkyy koko kaupanhinta, eli laite, lisäosat, huoltosopimus, koulutus, extramäärä vaihto-osia, jne. Mutta eiköhän se mene niin, että laite on laite ja se näkyy tuloksissa laitemyynnissä ja muut kilkkeet jatkuvassa liikevaihdossa.

This is indeed the data from which I also took the 180 k€/device used in the calculations. It really depends on the sales mix, etc., how an individual half-year turns out. The whole set looks like this   Previously indeed yes, nowadays almost exclusively capex sales for Nexstim. There might still be some tails from old contracts in recurring revenue, but mainly we can think that equipment sales = equipment revenue.

Estimating device prices is indeed quite tricky, and you listed the reasons for that very well. Digging up the price of an individual device from previous years’ revenue is also challenging because the diagnostics device generation changed last fall. In investor meetings, it has been stated that the price of a diagnostics device is around €300,000 and a therapy device is around €200,000. I would assume that the price of a combination device is somewhat higher than that of a standalone diagnostics device. Then, on top of that, the TMS-EEG system includes the EEG gear, so one could assume it is the most expensive version of all. However, in my own estimate yesterday, I tried to use very pessimistic prices for those device sales, because even with those, it can be concluded that analyst forecasts will be beaten this year, even if not a single additional device is sold for the rest of the year. I wonder a bit what prices NuWays used to calculate the required number of devices, but we’ll let that slide. After all, they have been following Nexstim for many years less than I have

We indeed don’t know the exact selling prices. Information can be found on Hilma regarding €300k equipment sold to the public sector, but financial statements suggest significantly lower selling prices. There is substantial variation between years and especially between half-years. Delivery and payment dates likely don’t always fall into the same quarter in the reports. Average prices could, of course, still be calculated by equipment type, but this level of precision has been sufficient for me for now.  I remember hearing at some point that equipment has also been sold on installment plans so that the selling price would be reflected in recurring revenue rather than equipment sales. Help out someone with a poor memory—was that really the case? Another, albeit much rougher, approach is to track how much revenue has been generated per delivered system across different years. That figure has hovered around €300k.  Now, let’s estimate this year: - H1/2026 revenue is known. It stands at €5.2M. There are at least 28 system deliveries in H2/2026. If using an average price of €185k, that would generate €5.2M in revenue. Assuming recurring revenue in H2 drops by -30% compared to the same period last year, recurring revenue would amount to €1.2M. I don’t know if it will decline that much, since, among other things, KUH (KYS) just ordered €320k worth of consumables. Additionally, €0.4M in revenue recognition is expected from Sinaptica. With these—what I consider very conservative—estimates, Nuways’ forecast of €12M in revenue would be reached at this point in the year. - Alternatively, using the rougher estimate where revenue comes to about €300k per delivered system, the year-to-date delivery volume leads to the same €12M figure.

Even there, the target is 46 planes for the full year. So with just one batch of ten plus a few individual planes, we’d blow past that with ease. There’s definitely still a chance for an upside surprise here. Of course, if the next batch of ten is delayed, I can’t say whether they’ll all be delivered this year. But in the bigger picture, it doesn’t really matter when the deliveries actually land. It mostly just affects this year’s EPS.

Nexstim

Paris MidCap conference feedback: Brainlab has the strategic fit and the installed base, to significantly scale Nexstim's NBS systems. Estimates unchanged. We remain with BUY and a PT of € 12...

Paris MidCap conference feedback: Brainlab has the strategic fit and the installed base, to significantly scale Nexstim's NBS systems. Estimates unchanged. We remain with BUY and a PT of € 12.

Privacy preferences

Nexstim: Conference feedback: Brainlab is set to scale NBS systems - NuWays AG Research

Nexstim: Conference feedback: Brainlab is set to scale NBS systems - NuWays AG Research